Business
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
The USPTO issued the first of its kind patent, which provides IP protection through October 2036 NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics,
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The USPTO issued the first of its kind patent, which provides IP protection through October 2036\n\n\nNEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,793,525 related to novel 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers. This patent is also the first of its kind, expiring on October 5, 2036. \n\n \n \n \n \n \n \n\n \nNumerous cancer types, including breast, prostate, bladder, and pancreatic cancers, share a similar oncogenic lineage through hyperactivation of a biochemical signaling cascade that promotes cancer initiation, progression, and metastases. This cancerous signal \"hijacking\" is controlled by two proteins, MAPK-interacting kinases 1 and 2 (or MNK 1/2); therefore, restoring control of the signaling pathway promotes programmed cell death (apoptosis) and inhibits cell growth. Researchers at UMB discovered novel 13-cis-retinoic acid metabolism blocking agent (RAMBAs) retinamides that are targeted to interrupt the MNK1/2-driven signaling pathway as potential therapeutics for various cancers. The potential therapeutic utility of these novel RAMBAs was shown in tumor xenograft animal models for both breast and prostate cancer. \nLast year, Hoth Therapeutics announced that it had entered into a Commercial Licensing Agreement with University of Maryland, Baltimore for the development of HT-003, a related but chemically different RAMBA, being developed for the treatment of acne and psoriasis. \n\"With this patent, Hoth Therapeutics continues to bolster its diverse IP portfolio, which now contains multiple patents related to both oncology treatments and dermatological disorders,\" stated, Robb Knie, Chairman and CEO of Hoth Therapeutics. \"We look forward to progressing towards additional breakthroughs throughout our entire biopharmaceutical pipeline in the near future.\"\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suf...